Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cipla Lines Up Advair But Costs Will Flatten High-Value Launches

Higher R&D Costs And Market-Driven Inflation Expected In 2022/23

Executive Summary

A generic version of Advair is high on Cipla’s plans for its current financial year ending in March 2023. Management discussed the high-value respiratory asset and the company’s further prospects during the Indian firm’s annual earnings call, which included the company passing $1bn in sales for its domestic branded prescription business.

You may also be interested in...

Lupin Urged To ‘Put US In Order’ As It Slides To Annual Pre-Tax Loss

Lupin’s 2021/22 financial year results revealed weakness in its core US generics business amid challenging market conditions. The Indian firm will continue to throw its weight behind its domestic business while rebuilding the US operation with more complex, high-value launches.

Hikma Warns Of Renewed Pricing Pressure On US Generics

Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.

Cipla Files ANDA For Advair Rival

Cipla has revealed that it has now filed its ANDA for a US rival to Advair Diskus. The FDA is already considering Hikma’s generic, while Mylan’s Wixela Inhub version has been on the market for well over a year.


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts